CAMP4 Therapeutics

Contributing Author

Recent Articles by CAMP4 Therapeutics

Dec-18	CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock CAMP GlobeNewswire
Dec-18	CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries CAMP GlobeNewswire
Dec-12	CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMP GlobeNewswire
Nov-14	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMP GlobeNewswire
Nov-06	CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights CAMP GlobeNewswire
Oct-01	CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 CAMP GlobeNewswire
Sep-10	CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders CAMP GlobeNewswire
Aug-14	CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights CAMP GlobeNewswire
May-16	CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting CAMP GlobeNewswire
May-13	CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights CAMP GlobeNewswire